ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Metformin

Also written as “metformin”, “Metformin XR” and “Fenofibrate /Metformin”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus · Obesity · Fasting · Polycystic Ovary Syndrome, led by 48 companies.

Drug pageMetformin: every studyMany companies study it; this page follows only the 215 they lead. All 1,290 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 9, 2005215 company-led studies, 7 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only290 open or runningphase 3since Nov 9, 2005Nov 9, 2005none ahead
Merckits history only190 open or runningphase 4since Oct 9, 2009Feb 15, 2005none ahead
Sanofiits history only160 open or runningphase 4since Jul 28, 2006Sep 30, 2002none ahead
GlaxoSmithKlineits history only140 open or runningphase 4since Oct 17, 2005Sep 3, 2003none ahead
Takedaits history only120 open or runningphase 4since Sep 17, 2008Jul 30, 2008none ahead
Merck KGaA, Darmstadt, Germanyits history only90 open or runningphase 4since Dec 30, 2011Dec 30, 2011none ahead
Teva Pharmaceutical Industriesits history only90 open or runningphase 1since Jan 30, 2009Jan 30, 2009none ahead
Viatrisits history only80 open or runningphase 1since Mar 30, 2008Mar 30, 2008none ahead
ADIUMits history only70 open or runningno phasesince Jun 3, 2026Jun 3, 2026none ahead
LG Chemits history only70 open or runningphase 3since Feb 6, 2013Aug 22, 2011none ahead

Also a collaborator on its studies: Parexel, PT Pharma Metric Labs, Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene, Eli Lilly and Merck, S.L., Spain.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 39 studies since Oct 5, 2015.

  1. Dec 18, 2024Phase 3 study in LongevityAgelessRx · NCT07092618 · 150 planned · United States
  2. Jan 20, 2025Phase 1 study in Diabetes Mellitus, Type 2Gedeon Richter Plc. · NCT06792968 · 64 enrolled · Russian Federation
  3. Feb 7, 2025Phase 1 study in Diabetes Mellitus, Type 2Gedeon Richter Plc. · NCT06823856 · 64 enrolled · Russian Federation
  4. Feb 19, 2025Nabiqasim Industries (Pvt)’s first study: phase 4 study in Diabetes MellitusNew to Nabiqasim Industries (Pvt)Nabiqasim Industries (Pvt) · NCT06862739 · 800 planned · Pakistan
  5. Jul 16, 2025Boryung Pharmaceutical’s first studies: 2 phase 1 studies in Diabetes MellitusNew to Boryung PharmaceuticalBoryung Pharmaceutical · NCT07083401, NCT07083388
  6. Aug 12, 2025Phase 1 study in HealthyMerck · NCT07121959 · 14 enrolled · United States
  7. Oct 27, 2025Phase 1 study in HealthyMerck · NCT07222098 · 16 enrolled · United States
  8. Nov 24, 2025Phase 1 study in Fed ConditionsLG Chem · NCT07333742 · 50 enrolled · South Korea
  9. Dec 10, 2025Aspargo Labs’ first studies: 2 phase 1 studies in Healthy VolunteerNew to Aspargo LabsAspargo Labs · NCT07300033, NCT07300020
  10. Jan 23, 2026Phase 1 study in Healthy VolunteersLG Chem · NCT07399470 · 58 enrolled · South Korea
  11. Feb 2, 2026Phase 1 study in FastingLG Chem · NCT07396844 · 28 enrolled · Thailand
  12. Apr 7, 2026Phase 1 study in HealthyMerck · NCT07530289 · 12 enrolled · United States
  13. Jun 3, 2026ADIUM’s first studies: 3 no phase studies in Bioequivalence Study in Healthy SubjectsNew to ADIUMADIUM · NCT07633054, NCT07633041, NCT07633028
  14. Aug 10, 20264 no phase studiesADIUM · NCT07763964, NCT07763951, NCT07763912 and 1 more

TargetBeta

“Mitochondrial complex I (NADH dehydrogenase) inhibitor; Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor”ChEMBL 37, by rule

Studies

The newest 60 of 215 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07763964Bioequivalance · Mexico–CompletedADIUMDec 19, 202546
NCT07763951Bioequivalance · Mexico–CompletedADIUMDec 14, 202546
NCT07763912Bioequivalence · Mexico–CompletedADIUMDec 5, 202546
NCT07763899Bioequivalance · Mexico–CompletedADIUMNov 30, 202546
NCT07633054Bioequivalence Study in Healthy Subjects · Mexico–CompletedADIUMNov 24, 202542
NCT07633041Bioequivalence Study in Healthy Subjects · Mexico–CompletedADIUMApr 4, 202542
NCT07633028Bioequivalence Study in Healthy Subjects · Mexico–CompletedADIUMApr 8, 202542
NCT07530289Healthy · United States1CompletedMerckMay 23, 202612
NCT07396844Fasting · Thailand1CompletedLG ChemJun 26, 202628
NCT07399470Healthy Volunteers · South Korea1CompletedLG ChemFeb 6, 202658
NCT07300033Healthy Volunteer1Not yet recruitingAspargo LabsJul 15, 202624
NCT07300020Healthy Volunteer1Not yet recruitingAspargo LabsJun 15, 202624
NCT07333742Fed Conditions · South Korea1CompletedLG ChemNov 27, 202550
NCT07222098Healthy · United States1CompletedMerckDec 14, 202516
NCT07121959Healthy · United States1CompletedMerckSep 13, 202514
NCT07083401Diabetes Mellitus · South Korea1RecruitingBoryung PharmaceuticalJul 5, 202640
NCT07083388Diabetes Mellitus · South Korea1RecruitingBoryung PharmaceuticalJul 3, 202652
NCT06862739Diabetes Mellitus · Pakistan4RecruitingNabiqasim Industries (Pvt)Apr 30, 2026800
NCT06823856Diabetes Mellitus, Type 2 · Russian Federation1CompletedGedeon Richter Plc.May 21, 202564
NCT06792968Diabetes Mellitus, Type 2 · Russian Federation1CompletedGedeon Richter Plc.Apr 6, 202564
NCT07092618Longevity · United States3RecruitingAgelessRxAug 2025150
NCT06766500Diabetes Mellitus, Type 2 · Russian Federation1CompletedGedeon Richter Plc.Feb 28, 202564
NCT06233201Healthy Subjects1Not yet recruitingBio-innovaJul 14, 202434
NCT06160414Healthy · United Kingdom1CompletedAstraZenecaFeb 5, 202420
NCT05823883DW6014 · Korea, Republic of1UNKNOWNDong Wha PharmaceuticalJul 202330
NCT05823870Healthy Subjects · Korea, Republic of1CompletedDong Wha PharmaceuticalMar 6, 202332
NCT05874180Healthy Subjects · Korea, Republic of1CompletedDong Wha PharmaceuticalFeb 1, 202331
NCT05874167Healthy Subjects · Korea, Republic of1CompletedDong Wha PharmaceuticalOct 11, 202250
NCT05768360Healthy Male Subjects · Germany1CompletedAstraZenecaJun 24, 20236
NCT05753371Drug Use · Indonesia–CompletedPT. Pyridam Farma TbkMar 24, 202224
NCT05463094Healthy · Germany1CompletedMerck KGaA, Darmstadt, GermanyJan 3, 202384
NCT05337969To Determine Bioequivalence Under Fed Conditions–CompletedAET Laboratories PrivateDec 201560
NCT05329857To Determine Bioequivalence Under Fed Conditions–CompletedAET Laboratories PrivateJan 201660
NCT05167513Diabetes Mellitus, Type 2 · Pakistan4CompletedGetz PharmaApr 28, 2022188
NCT05132023Healthy · Egypt1CompletedGenuine Research Center, EgyptApr 2, 201926
NCT05124730Pharmacokinetics · Czechia1CompletedJoint Stock Company "Farmak"May 29, 202144
NCT05124717Pharmacokinetics · Czechia1CompletedJoint Stock Company "Farmak"Jul 3, 201928
NCT05123781Pharmacokinetics · Czechia1CompletedJoint Stock Company "Farmak"Apr 17, 201928
NCT05125575Pharmacokinetics · Czechia1CompletedJoint Stock Company "Farmak"Jan 19, 201928
NCT05064488Healthy · Germany1CompletedMerck KGaA, Darmstadt, GermanyDec 10, 202140
NCT04899349Breast Neoplasms · United States, Malaysia2TerminatedNovartisMay 10, 20232
NCT04855513Pre-Eclampsia · Qatar–UNKNOWNHamad MedicalApr 24, 2023414
NCT04841096Diabetes Mellitus, Type 2 · Mexico3CompletedLaboratorios Silanes S.A. de C.V.Mar 15, 2024162
NCT04684420Diabetes Mellitus · Korea, Republic of1CompletedMerck KGaA, Darmstadt, GermanyMar 11, 202281
NCT04604678COVID-19 · United States2WithdrawnAgelessRxAug 20210
NCT04428086Solid Tumor, Adult · China1CompletedJiangsu HengRui MedicineAug 22, 202119
NCT04317703Diabetes Mellitus, Type 2 · Thailand1CompletedLG ChemSep 5, 202040
NCT04231435Healthy Volunteers · United States1CompletedBristol-Myers SquibbFeb 19, 202024
NCT04050098Type2 Diabetes1UNKNOWNLG ChemNov 30, 201924
NCT03880825Healthy Subjects · United States1CompletedCortendo ABMay 3, 201932
NCT03826602Drug-drug Interaction · United States1CompletedPfizerMar 8, 201918
NCT03593707Healthy Volunteers · Belgium1CompletedPfizerJan 17, 201918
NCT03566810Diabetes Mellitus · China1CompletedMerck KGaA, Darmstadt, GermanyNov 28, 201854
NCT03467971Healthy · Mexico1CompletedMerck KGaA, Darmstadt, GermanyApr 22, 201821
NCT03467945Healthy · Germany1CompletedMerck KGaA, Darmstadt, GermanyApr 29, 201840
NCT03458208Lecithin Cholesterol Acyltransferase Deficiency · Russian Federation1CompletedGeropharmMar 2, 201718
NCT03452306Lecithin Cholesterol Acyltransferase Deficiency · Russian Federation1CompletedGeropharmJul 22, 201728
NCT03393208Diabetes Mellitus · China1CompletedMerck KGaA, Darmstadt, GermanyJan 29, 201844
NCT03216278Lecithin Cholesterol Acyltransferase Deficiency · Brazil1CompletedAstraZenecaMay 22, 2018284
NCT03787017Healthy Volunteers · Korea, Republic of1CompletedHandokAug 201436

How it is read

Names in the registry

  • “Metformin”, 95 entries
  • “metformin”, 33 entries
  • “Metformin XR”, 11 entries
  • “Fenofibrate /Metformin”, 6 entries
  • “Sitagliptin/Metformin FDC”, 5 entries

Codes read as this program: EFB0027.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.